Share price · BCDA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BCDA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 20 Oct 2026+15.9%
- Day beforeBioCardia: Other material event
- 17 Sep 2026-11.2%
Nothing announced by BCDA that day or the session before.
- 14 Jul 2026-12.1%
Nothing announced by BCDA that day or the session before.
- 7 Jul 2026-12.8%
Nothing announced by BCDA that day or the session before.
- 12 Jun 2026+10.0%
- 9 Jun 2026-6.5%
- Day beforeBioCardia: Other material event
- 8 Jun 2026-10.7%
- 5 Jun 2026+12.0%
- 18 May 2026-10.9%
- 4 Mar 2026-6.3%
- Day beforeBioCardia: Regulation FD disclosure
Share of unusual movement by asset
For each asset, the share of BCDA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Cardiac cell therapyCell therapy | Heart Failure Ischemic Heart Failure |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $1.2M | $2.2M | $1.8M-$1.7M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $0.9M | $4.1M | $1.6M-$1.7M operating cash flow | report ↗ |
| 2026-Q1 | — | $1.2M | $0.9M | $2.3M-$1.7M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $0.9M | $5.3M | $1.5M-$1.7M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $1.4M | $1.0M | $2.0M-$1.6M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $1.5M | $0.9M | $2.7M-$1.6M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $0.9M | $4.9M | $1.7M-$2.6M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $0.8M | $1.4M | $1.6M-$1.3M operating cash flow | report ↗ |
| 2024-Q1 | $0.1M | $1.2M | $0.9M | $2.3M-$1.5M operating cash flow | report ↗ |
| 2023-Q3 | $0.4M | $1.9M | $1.8M | $2.6M-$2.4M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $2.3M | $4.3M | $3.4M-$3.1M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $2.4M | $4.9M | $3.5M-$2.6M operating cash flow | report ↗ |
| 2022-Q3 | $0.2M | $2.1M | $6.7M | $3.1M-$2.0M operating cash flow | report ↗ |
| 2022-Q2 | $1.0M | $2.3M | $8.6M | $2.5M-$2.6M operating cash flow | report ↗ |
| 2022-Q1 | $0.1M | $2.2M | $9.9M | $3.3M-$2.9M operating cash flow | report ↗ |
| 2021-Q3 | $0.8M | $2.2M | $16M | $2.7M-$2.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $5.0M | $2.5M | $2.1M-$7.4M operating cash flow | report ↗ |
For FY2025, BioCardia reported revenue of $0M, down 100.0% YoY from $0.06M, and R&D spend of $4.96M, up 13.0% YoY. Cash and equivalents were $2.5M, with a net loss of $8.23M and quarterly net burn of $8.23M.
Clinically, the company presented two-year CardiAMP HF results at ACC 2025 and echocardiography outcomes at THFT in March 2026, while its Helix Pre-Submission was accepted by FDA with a meeting expected in Q2 2026. CardiAMP HF II enrollment is ongoing with four activated sites, CardiAMP CMI roll-in results were submitted for Euro PCR, and the CardiALLO low-dose cohort completed without treatment-emergent adverse events. CMS has designated the CardiAMP trials for Medicare coverage.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.1M | $4.4M | $2.4M | $2.0M-$8.0M operating cash flow | report ↗ |
| 2023-FY | $0.5M | $7.7M | $4.9M | $2.9M-$10.0M operating cash flow | report ↗ |
| 2022-FY | $1.4M | $8.8M | $7.4M | $3.0M-$11M operating cash flow | report ↗ |
| 2021-FY | $1.0M | $8.6M | $13M | $3.2M-$10M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 34 purchases ($170K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-16 | Altman Peter · director, President and CEO | Open-market purchase | 300 | $0.95 | $285 | Form 4 |
| 2026-10-15 | Altman Peter · director, President and CEO | Open-market purchase | 200 | $0.95 | $190 | Form 4 |
| 2026-09-29 | Altman Peter · director, President and CEO | Open-market purchase | 1,000 | $1.03 | $1K | Form 4 |
| 2026-09-23 | Altman Peter · director, President and CEO | Open-market purchase | 1,900 | $1.05 | $2K | Form 4 |
| 2026-09-03 | Altman Peter · director, President and CEO | Open-market purchase | 800 | $1.09 | $872 | Form 4 |
| 2026-08-17 | Altman Peter · director, President and CEO | Open-market purchase | 5,400 | $0.93 | $5K | Form 4 |
| 2026-08-13 | Altman Peter · director, President and CEO | Open-market purchase | 1,900 | $0.92 | $2K | Form 4 |
| 2026-07-29 | Altman Peter · director, President and CEO | Open-market purchase | 5,000 | $0.78 | $4K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 18 reporting institutions held 0.7M shares ($806K, 4.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | CM Management, LLC | 130,000 | $157K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 124,591 | $151K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 94,287 | $114K |
| 4 | VANGUARD FIDUCIARY TRUST CO | 66,270 | $80K |
| 5 | CITADEL ADVISORS LLC | 63,384 | $77K |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 38,827 | $47K |
| 7 | Pingora Partners LLC | 35,739 | $43K |
| 8 | BROWN ADVISORY INC | 35,538 | $43K |
| 9 | XTX Topco Ltd | 24,270 | $29K |
| 10 | COMMONWEALTH EQUITY SERVICES, LLC | 18,283 | $22K |
| 11 | TWO SIGMA SECURITIES, LLC | 14,780 | $18K |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 13,900 | $17K |
| 13 | MORGAN STANLEY | 3,105 | $4K |
| 14 | Tower Research Capital LLC (TRC) | 2,978 | $4K |
| 15 | Vanguard Global Advisers, LLC | 268 | $324 |